These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

388 related items for PubMed ID: 19655820

  • 1. Nebivolol: in the treatment of hypertension in the US.
    Baldwin CM, Keam SJ.
    Am J Cardiovasc Drugs; 2009; 9(4):253-60. PubMed ID: 19655820
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension.
    Germino FW.
    Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484
    [Abstract] [Full Text] [Related]

  • 3. Nebivolol: a third-generation beta-blocker for hypertension.
    Cheng JW.
    Clin Ther; 2009 Mar; 31(3):447-62. PubMed ID: 19393838
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and tolerability of nebivolol in stage I-II hypertension: a pooled analysis of data from three randomized, placebo-controlled monotherapy trials.
    Weiss RJ, Saunders E, Greathouse M.
    Clin Ther; 2011 Sep; 33(9):1150-61. PubMed ID: 21864908
    [Abstract] [Full Text] [Related]

  • 5. Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial.
    Weiss RJ, Stapff M, Lin Y.
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):129-40. PubMed ID: 23519546
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and tolerability of nebivolol: does age matter? A retrospective analysis of three randomized, placebo-controlled trials in stage I-II hypertension.
    Germino FW, Lin Y, Pejović V, Bowen L.
    Ther Adv Cardiovasc Dis; 2012 Oct; 6(5):185-99. PubMed ID: 23008339
    [Abstract] [Full Text] [Related]

  • 7. Nebivolol in hypertension: a double-blind placebo-controlled multicenter study assessing its antihypertensive efficacy and impact on quality of life.
    Van Bortel LM, Breed JG, Joosten J, Kragten JA, Lustermans FA, Mooij JM.
    J Cardiovasc Pharmacol; 1993 Jun; 21(6):856-62. PubMed ID: 7687708
    [Abstract] [Full Text] [Related]

  • 8. [Nebivolol, a third generation beta blocker: the modern treatment of hypertension. Results of a multicentric observational study].
    von Fallois J, Faülhaber HD.
    Fortschr Med Orig; 2000 Jul 27; 118 Suppl 2():77-82. PubMed ID: 15700490
    [Abstract] [Full Text] [Related]

  • 9. Nebivolol: a third-generation beta-adrenergic blocker.
    Veverka A, Nuzum DS, Jolly JL.
    Ann Pharmacother; 2006 Jul 27; 40(7-8):1353-60. PubMed ID: 16822893
    [Abstract] [Full Text] [Related]

  • 10. Comparison of Nebivolol monotherapy versus Nebivolol in combination with other antihypertensive therapies for the treatment of hypertension.
    Papademetriou V.
    Am J Cardiol; 2009 Jan 15; 103(2):273-8. PubMed ID: 19121451
    [Abstract] [Full Text] [Related]

  • 11. The role of the new beta-blockers in treating cardiovascular disease.
    Weber MA.
    Am J Hypertens; 2005 Dec 15; 18(12 Pt 2):169S-176S. PubMed ID: 16373195
    [Abstract] [Full Text] [Related]

  • 12. Nebivolol: new therapy update.
    Sule SS, Frishman W.
    Cardiol Rev; 2006 Dec 15; 14(5):259-64. PubMed ID: 16924166
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial.
    Grassi G, Trevano FQ, Facchini A, Toutouzas T, Chanu B, Mancia G.
    Blood Press Suppl; 2003 Dec 15; 2():35-40. PubMed ID: 14761075
    [Abstract] [Full Text] [Related]

  • 14. Beta-blockers in the management of hypertension: focus on nebivolol.
    Wojciechowski D, Papademetriou V.
    Expert Rev Cardiovasc Ther; 2008 Apr 15; 6(4):471-9. PubMed ID: 18402537
    [Abstract] [Full Text] [Related]

  • 15. Nationwide efficacy-safety study of nebivolol in mildly hypertensive patients.
    Cleophas TJ, Agrawal R, Lichtenthal A, Mäkel W, Fici F.
    Am J Ther; 2006 Apr 15; 13(3):192-7. PubMed ID: 16772759
    [Abstract] [Full Text] [Related]

  • 16. Nitric oxide mechanisms of nebivolol.
    Maffei A, Lembo G.
    Ther Adv Cardiovasc Dis; 2009 Aug 15; 3(4):317-27. PubMed ID: 19443516
    [Abstract] [Full Text] [Related]

  • 17. Nebivolol in the management of essential hypertension: a review.
    McNeely W, Goa KL.
    Drugs; 1999 Apr 15; 57(4):633-51. PubMed ID: 10235696
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: a randomized, multicentre, double-blind study.
    Rosei EA, Rizzoni D, Comini S, Boari G, Nebivolol-Lisinopril Study Group.
    Blood Press Suppl; 2003 May 15; 1():30-5. PubMed ID: 12800985
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis.
    Van Bortel LM, Fici F, Mascagni F.
    Am J Cardiovasc Drugs; 2008 May 15; 8(1):35-44. PubMed ID: 18303936
    [Abstract] [Full Text] [Related]

  • 20. Nebivolol monotherapy in younger adults (younger than 55 years) with hypertension: a randomized, placebo-controlled trial.
    Giles TD, Khan BV, Lato J, Brener L, Ma Y, Lukic T.
    J Clin Hypertens (Greenwich); 2013 Sep 15; 15(9):687-93. PubMed ID: 24034663
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.